Jove
Visualize
联系我们

相关概念视频

Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

573
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
573
Blind Procedures02:07

Blind Procedures

13.4K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
13.4K
Predicting Reaction Outcomes02:24

Predicting Reaction Outcomes

10.8K
Kinetics describes the rate and path by which a reaction occurs. In contrast, thermodynamics deals with state functions and describes the properties, behavior, and components of a system. It is not concerned with the path taken by the process and cannot address the rate at which a reaction occurs. Although it does provide information about what can happen during a reaction process, it does not describe the detailed steps of what appears on an atomic or a molecular level. On the other hand,...
10.8K
Outcomes of Glycolysis01:13

Outcomes of Glycolysis

107.2K
Nearly all the energy used by cells comes from the bonds that make up complex organic compounds. These organic compounds are broken down into simpler molecules, such as glucose. As a result, cells extract energy from glucose over many chemical reactions—a process called cellular respiration.
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
107.2K
Overview of the Cardiovascular System01:14

Overview of the Cardiovascular System

11.9K
The cardiovascular system is a vital transportation system in the body. It comprises the heart and blood vessels and facilitates the exchange of gases, nutrients, and waste products.
Heart
The heart is the central pump of the cardiovascular system that circulates blood throughout the body. It comprises two atria receiving the blood and two ventricles pumping blood out of the heart. Their rhythmic contractions, called heartbeats, ensure that blood flow remains continuous.
Blood Vessels
Blood...
11.9K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.0K
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策
  1. 首页
  2. 2型糖尿病和心血管疾病患者的albiglutide和心血管结果 (harmony Outcomes):一个双盲,随机的安慰剂对照试验
  1. 首页
  2. 2型糖尿病和心血管疾病患者的albiglutide和心血管结果 (harmony Outcomes):一个双盲,随机的安慰剂对照试验

相关实验视频

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

2型糖尿病和心血管疾病患者的Albiglutide和心血管结果 (Harmony Outcomes):一个双盲,随机的安慰剂对照试验

Adrian F Hernandez1, Jennifer B Green1, Salim Janmohamed2

  • 1Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.

Lancet (London, England)
|October 7, 2018

在PubMed 上查看摘要

概括
此摘要是机器生成的。

作为一种类似于葡萄糖的1受体激动剂,阿尔比古丁可显著降低2型糖尿病患者的重大心血管不良事件. 这表明它在预防心血管死亡,心肌梗塞或中风方面的有效性.

更多相关视频

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.1K
Fundus Photography as a Convenient Tool to Study Microvascular Responses to Cardiovascular Disease Risk Factors in Epidemiological Studies
10:11

Fundus Photography as a Convenient Tool to Study Microvascular Responses to Cardiovascular Disease Risk Factors in Epidemiological Studies

Published on: October 22, 2014

19.7K

相关实验视频

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.1K
Fundus Photography as a Convenient Tool to Study Microvascular Responses to Cardiovascular Disease Risk Factors in Epidemiological Studies
10:11

Fundus Photography as a Convenient Tool to Study Microvascular Responses to Cardiovascular Disease Risk Factors in Epidemiological Studies

Published on: October 22, 2014

19.7K

科学领域:

  • 心脏病学
  • 内分泌学
  • 药理学

背景情况:

  • 葡萄糖类1受体激动剂的结构和临床效果各不相同.
  • 在2型糖尿病中每周服用一次阿尔比格卢提德对心血管的影响以前是未知的.
  • 需要评估albiglutide在预防重大心血管不良事件方面的安全性和有效性.

研究的目的:

  • 确定阿尔比格卢提德的心血管安全性和疗效.
  • 评估阿尔比古在预防心血管死亡,心肌梗塞或中风方面的作用.
  • 在高风险患者中比较阿尔比格卢提德与安慰剂的影响.

主要方法:

  • 这是一项双盲,随机,安慰剂对照试验,涉及9463名2型糖尿病和心血管疾病患者.
  • 患者平均每周接受皮下阿尔比格卢提德或安慰剂治疗时间为1. 6年.
  • 主要结局:第一次发生心血管死亡,心肌梗塞或中风.

主要成果:

  • 在降低初级复合结果方面,阿尔比格卢提德优于安慰剂 (HR 0. 78; 95% CI 0. 68- 0. 90; p = 0. 0006).
  • 与安慰剂 (9%) 相比,阿尔比格卢提德组的重大心血管不良事件发生率较低.
  • 两组之间没有发现严重不良事件的显著差异,包括胰腺炎和胰腺癌.

结论:

  • 在2型糖尿病和已确定的心血管疾病患者中,阿尔比格卢提德在减少主要心血管不良事件方面表现优越.
  • 在综合心血管风险降低策略中应考虑使用基于证据的葡萄糖类1受体激动剂,如阿尔比格卢提德.
  • 对于2型糖尿病患者来说,阿尔比格卢提德是一种有价值的治疗选择.